EYLEA HD FDA Approval for Wet AMD and DME
Key Questions
What is the latest FDA approval for EYLEA HD?
The FDA has updated the label for EYLEA HD to allow dosing intervals of up to 20 weeks after one year of treatment for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). This approval is supported by 96-week data from the PULSAR and PHOTON trials.
What dosing schedule does the updated FDA label allow for EYLEA HD?
After one year, patients with nAMD or DME can extend dosing intervals up to 20 weeks with EYLEA HD. This change aims to reduce treatment burden while maintaining efficacy.
What data from clinical trials supports the extended dosing for EYLEA HD?
The PULSAR and PHOTON trials at 96 weeks showed high proportions of patients achieving extended intervals with sustained efficacy and safety. Real-world SPECTRUM data reinforces early improvements in retinal fluid and visual acuity.
How does EYLEA HD reduce treatment burden for patients?
The approval enables up to 20-week dosing intervals after one year, potentially lowering the frequency of injections for wet AMD and DME patients. This is backed by trial data confirming maintained efficacy and safety.
What makes EYLEA HD unique among anti-VEGF treatments?
EYLEA HD is approved as the first and only injectable anti-VEGF with dosing intervals up to 20 weeks (about 5 months) for wet AMD and DME after initial treatment. Recent reports confirm these extended dosing details in clinical practice.
FDA label updated confirming up to 20-week (5-month) dosing after 1 year for nAMD/DME, backed by 96-week PULSAR/PHOTON and SPECTRUM real-world data on extended intervals, efficacy, and reduced burden. Recent reports reinforce widest dosing options in practice.